Navigation Links
Results of phase III study on Labopharm's novel antidepressant published in Psychiatry (Edgemont) Journal
Date:5/19/2009

                 - Company to Also Present Clinical Data at
                        Upcoming Scientific Meeting -

LAVAL, QC, May 19 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced the publication of Extended Release Trazodone in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Study in the May 2009 issue of the journal Psychiatry (Edgemont) (Volume 6, Number 5) (www.psychiatrymmc.com). The results of this Phase III clinical trial (study 04ACL3-001), which were originally reported by the Company in February 2008, demonstrate clear benefits for Labopharm's novel antidepressant.

More than 120 million people around the world suffer from depression. Treatment is often challenging because response to antidepressant drug therapy can vary significantly. Clinically depressed patients are typically treated with two different types of drug therapy: selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs)). However, some 40 to 50% of patients being treated for depression stop taking these antidepressant drugs within the first 12 months of treatment. Frequently cited reasons for discontinuing therapy include suboptimal efficacy on depression symptoms, exacerbation of sleep disturbance, increased agitation, slow onset of action, sexual dysfunction and weight gain.

Labopharm's novel formulation of the antidepressant trazodone is designed to optimize the efficacy of trazodone, and address the major challenges in treating depression.

Summary of Results of Labopharm's Phase III Clinical Trial on Trazodone

Labopharm's multi-center phase III clinical trial compared the efficacy and safety of Labopharm's novel trazodone formulation to placebo in patien
'/>"/>

SOURCE Labopharm Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. International Isotopes Inc. Announces First Quarter 2009 Financial Results
2. Encision Reports Fourth Quarter and Fiscal Year 2009 Results
3. Uroplasty to Issue Fourth Fiscal Quarter and Full Year Results on June 4, 2009
4. BMP Sunstone Reports First Quarter 2009 Financial Results
5. Neurocrine Announces Full Year Results from 603 Study (Petal Study) of Elagolix for Treatment of Endometriosis Pain
6. Lotus Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results
7. Jiangbo Pharmaceuticals Reports Results for the Third Quarter of its Fiscal Year 2009
8. AdCare Health Systems, Inc. Turns Profitable; Reports 2009 First Quarter Earnings Results
9. Light Sciences Oncology Announces Results of Study on Immunotherapeutic Mechanism of Aptocine(TM), a Novel Light-Activated Drug Therapy for Cancer
10. Derma Sciences Reports First Quarter 2009 Results
11. NovaBay Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... signs of chronic inflammation in non-cancerous prostate tissue may ... cancer than those with no inflammation, according to results ... Johns Hopkins Kimmel Cancer Center. , The link between ... with so-called high-grade prostate cancer those with a ... presence of the most aggressive and rapidly growing prostate ...
(Date:4/17/2014)... study published today in PLOS Pathogens , children ... is common can mount an immune response to infection ... repeated bouts of high fever and illness and partially ... The findings may help researchers develop future interventions that ... parasite. , Each year, approximately 200 million cases of ...
(Date:4/17/2014)... the April issue of Immunity , Kevin J. ... Research, says it,s time to take a fresh look ... sepsis, which kills millions worldwide every year, including more ... into the bloodstream to fight an injury or infection ... maintaining good health without inflammation, wounds and infections ...
(Date:4/17/2014)... (April 17, 2014) Doctors who treat patients ... lymphangioleiomyomatosis (LAM) can face an agonizing treatment decision. ... the disease and help relieve shortness of breath. ... and sirolimus can cause potentially fatal complications following ... Dr. Daniel Dilling, medical director of Loyola University ...
(Date:4/17/2014)... By discovering a new mechanism that allows blood to ... UC Irvine and the Salk Institute have opened the ... stroke-induced brain damage. , A complex and devastating neurological ... primary reason for disability in the U.S. The blood-brain ... blood-borne material into the brain, causing the permanent deficits ...
Breaking Medicine News(10 mins):Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Study sheds light on how the immune system protects children from malaria 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:Study IDs new cause of brain bleeding immediately after stroke 2
... experts say , SUNDAY, Dec. 27 (HealthDay News) -- ... infants on human milk, relatively few continue breast-feeding for ... an entire year. , Why not stick it ... moms, but California researchers say they found that returning ...
... cardiovascular disease, diabetes, study found , FRIDAY, Dec. 25 ... between having heavy sons and cardiovascular death, but having underweight ... Previous research has already linked obesity to higher rates of ... Studies have also shown that very thin people may be ...
... , , BOULDER, Colo., Dec. 25 ... : LULULEMON AD IN YOGA JOURNAL MAGAZINE: EFFECTIVE ADVERTISING , Lululemon, the ... of the park. It,s the kind of ad that earns its maker ... see the ad, featuring a disabled yogini, visit elephantjournal.com: , ...
... ... together nanotechnology to focus on Sports injury prevention and training , ... Mission Viejo, Calif. (PRWEB) December 25, ... first subsidiary for sports based technologies called MVP Sports Technologies, Inc., , ,MVP Sports ...
... depending on how product is designed, study shows , ... blamed for everything from promoting youth violence to contributing to ... parents who planned on passing by the video game aisle ... video games can sharpen certain thinking skills, increasing cognitive speed ...
... Today,s passage of health care reform in the U.S. Senate ... a promise we will make to every person living in this ... will be able to afford coverage and insurance companies will not ... other steps will include final passage after conference committee, effective implementation ...
Cached Medicine News:Health News:Many Women Quit Breast-Feeding Early 2Health News:Many Women Quit Breast-Feeding Early 3Health News:Waylon Lewis of elephantjournal.com: Lululemon Ad; Naropa University Budget 2Health News:Applied Technology Holdings, Inc. Forms First New Subsidiary Called MVP Sports Technologies, Inc. 2Health News:Video Games Could Boost Certain Thinking Skills 2Health News:Video Games Could Boost Certain Thinking Skills 3Health News:A Promise to Keep. Senate Vote is the First Step Toward the Promise of Quality, Affordable Health Care for All 2
(Date:1/14/2014)... 2014  Luminex Corporation (Nasdaq: LMNX ) today announced ... of 2013 on Monday, February 3, 2014. A press release ... of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) ... operating highlights and financial results for the fourth quarter and ...
(Date:1/14/2014)... 14, 2014 Dynamic Healthcare Services, Inc. ("DHS"), a portfolio ... acquired Progressive Home Medical Equipment, Inc. ("Progressive") of ... of the acquisition were not disclosed. Progressive ... a wide range of sleep, mobility, and respiratory products to ...
(Date:1/14/2014)... 2014   NuAire , a manufacturer of ergonomically designed laboratory ... Koki of Japan to sell and ... . NuAire will utilize its network of sales professionals throughout ... to offer assistance in application use, product benefits and ...
Breaking Medicine Technology:Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3NuAire announces sales and service of Hitachi Koki centrifuges in North America 2
0.6mm Tip x10mm Shaft, Straight Shaft, 90 Degree Hook at Tip; overall length 120mm; in Titianium....
... SURPASS Perfusion Catheter is indicated ... stenotic portion of a coronary ... for the purpose of improving ... Catheters are also designed to ...
16mm from Mid-screw to Tips, blunt tips; overall length 110mm; Stainless Steel...
16mm from Mid-Screw to Blunt Tips, Gently Curved Blades; overall length 120mm; Stainless Steel...
Medicine Products: